Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026

Compass Therapeutics, Inc.

Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).
Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.
Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.
CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.
CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.